Pasithea advances PAS-004 in Phase 1 but burning cash; Nasdaq bid-price notice looms

Pasithea Therapeutics Corp. (NASDAQ: KTTA) - Quick read

One-line summary: Clinical-stage biotech advancing PAS-004 through multiple Phase 1 programs while burning cash; recent financing improved cash but company remains dependent on additional capital and faces a Nasdaq minimum bid-price notice.

Key facts & figures (from Form 10‑Q for quarter ended June 30, 2025)
* Cash and cash equivalents: $7,217,052 (June 30, 2025).
* Cash equivalents (money market funds): $6,207,926 of the cash balance.
* Working capital: $6,899,643 (June 30, 2025).
* Total assets: $17,009,142; Total liabilities: $1,830,697; Stockholders' equity: $15,178,445.
* Accumulated deficit: $(56,862,173).
* Net loss - three months ended June 30, 2025: $(3,716,157); six months: $(7,279,395).
* Loss from operations - quarter: $(3,810,899); six months: $(7,491,078).
* General & administrative (Q2): $1,662,223; Research & development (Q2): $2,148,676.
* Cash used in operating activities (six months): $(6,924,643).
* Net cash provided by financing activities (six months): $7,213,335 (ATM, public offering, warrant exercises).
* Shares outstanding: 7,443,577 (June 30, 2025) vs 1,394,263 (Dec 31, 2024).
* Weighted‑average common shares outstanding (basic & diluted): 5,641,251 (Q2 2025); loss per share Q2 2025: $(0.66) vs Q2 2024: $(3.71).
* Warrants outstanding: 9,772,262 (weighted avg exercise price $6.20); public warrant liability ~ $88,000; representative warrant liability $5,741 (Level 3).

What's happening inside the company
* Clinical progress: PAS‑004 IND cleared (Dec 2023). Ongoing FIH Phase 1 dose‑escalation trial at multiple sites (U.S. + Eastern Europe); company expects FIH study completion in 2026. Initiated Phase 1/1b NF1‑PN trial (May 2025) with sites in Australia, South Korea and the U.S.; June/July disclosures note cohort dosing and pharmacodynamic target engagement.
* Pipeline: Lead PAS‑004 (MEK inhibitor) advancing clinically; PAS‑003 (ALS) and PAS‑001 (schizophrenia) remain in discovery stage and have been partially de‑prioritized per R&D spend trends.
* Financing and capitalization: May 2025 public offering and ATM sales raised material proceeds (net ~ $4.2M from May offering; ATM net proceeds $2,010,782 in H1 2025; warrant exercises added ~$1.28M). Substantial share issuance drove outstanding shares to 7.44M and materially diluted per‑share loss vs prior-year periods.
* Corporate/operational: Prepaid expenses jumped to $1,301,705 (from $302,641), reflecting timing of paid clinical/manufacturing costs. Company has a financed D&O insurance payable ~$155,455. Several foreign subsidiaries were dissolved or discontinued; minor realized foreign translation losses recognized.
* Governance / market status: Received Nasdaq notice (June 23, 2025) for failure to meet $1.00 minimum bid price; company is considering options (including reverse split) to regain compliance.

Income statement - positives
* Per‑share metrics improved year‑over‑year: Q2 2025 basic/diluted loss per share $(0.66) vs $(3.71) in Q2 2024 - largely due to a much larger share base from financings (dilution improved EPS though not economics).
* R&D and G&A trending modestly down on a six‑month basis vs prior year: six‑month G&A down ~$266k (‑6.9%); six‑month R&D down ~$229k (‑5.6%) as preclinical programs were de‑prioritized-this may conserve cash while clinical focus continues.
* Recent financings materially improved immediate liquidity: net financing cash inflows of $7.21M for H1 2025 offset operating cash burn and increased cash balance vs year‑start.

Income statement - negatives
* Ongoing, sizable losses: net loss for six months of $(7,279,395) and operating cash burn of $(6,924,643) in H1 2025 - runway remains limited.
* Accumulated deficit large: $(56,862,173) - reflects multi‑year R&D spend with no product revenue.
* Dependency on dilution and capital markets: cash inflows came from equity offerings and warrant exercises; company states it will not have sufficient working capital for 12 months without additional funding - raising the risk of further dilution or adverse financing terms.
* Clinical spend increasing: clinical trials expense rose materially (FIH dose escalation + NF1 trial initiation), which will increase near‑term burn as trials progress.
* Market risk: Nasdaq bid‑price non‑compliance creates execution and perception risk; potential reverse split or other remedial actions could negatively affect liquidity and investor confidence.

Immediate investor takeaways / risks
* Positive: company is executing clinical milestones (PAS‑004 PD signal; trial initiations and cohort dosing) and has raised cash in H1 2025 to fund operations near term.
* Negative: cash runway is limited; company explicitly flags going‑concern uncertainty and dependence on additional equity/debt financing; continued net losses and clinical spend will require further capital and likely dilution.
* Market watch: monitor cash burn vs. enrollment progress, upcoming clinical readouts, warrant exercises, share count changes and Nasdaq compliance developments.

Source: Pasithea Therapeutics Corp. Form 10‑Q for quarter ended June 30, 2025 (financials and disclosures cited above).